KalVista Pharmaceuticals
KALV • NASDAQ
KalVista Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Benjamin L. Palleiko, with a market cap of $990.1M.
CEOBenjamin L. Palleiko
Next Earnings
Upcoming earnings announcement for KalVista Pharmaceuticals
Date
Saturday, May 9, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.44
Revenue Estimate
$37.3M
Earnings History
Past 12 earnings reports for KalVista Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 25, 2026 | Q4 2025 | —Est: -$0.53 | — | —Est: $30.9M | — | — |
| Nov 10, 2025 | Q3 2025 | -$0.92Est: -$1.04 | +11.5% | $13.7MEst: $6.3M | +116.2% |  10-Q |
| Sep 11, 2025 | Q1 2026 | -$1.12Est: -$0.94 | -19.1% | $1.4MEst: $2.0M | -27.7% | 10-Q |
| Jul 10, 2025 | Q4 2025 | -$0.99Est: -$0.81 | -22.2% | -Est: $11.4M | -100.0% | 10-K |
| Mar 12, 2025 | Q3 2025 | -$0.92Est: -$0.88 | -4.5% | - | — | 10-Q |
| Dec 5, 2024 | Q2 2025 | -$0.91Est: -$0.91 | 0.0% | - | — | 10-Q |
| Sep 5, 2024 | Q1 2025 | -$0.87Est: -$0.86 | -1.2% | - | — | 10-Q |
| Jul 11, 2024 | Q4 2024 | -$1.02Est: -$0.73 | -39.7% | - | — | 10-K |
| Mar 11, 2024 | Q3 2024 | -$0.84Est: -$0.77 | -9.1% | - | — | 10-Q |
| Dec 7, 2023 | Q2 2024 | -$0.80Est: -$0.79 | -1.3% | - | — | — |
| Sep 7, 2023 | Q1 2024 | -$0.74Est: -$0.86 | +14.0% | - | — | 10-Q |
| Jul 7, 2023 | Q4 2023 | -$0.77Est: -$0.94 | +18.1% | - | — | 10-K |